MeFirst: A Tailored Intervention to HPV Vaccine Decision Making
|ClinicalTrials.gov Identifier: NCT01769560|
Recruitment Status : Completed
First Posted : January 16, 2013
Last Update Posted : July 22, 2015
|Condition or disease||Intervention/treatment|
|Human Papillomavirus-Related Carcinoma||Behavioral: MeFirst Tailored Intervention|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||661 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Double (Participant, Investigator)|
|Primary Purpose:||Health Services Research|
|Official Title:||MeFirst: A Tailored Intervention to HPV Vaccine Decision Making|
|Study Start Date :||January 2013|
|Primary Completion Date :||April 2014|
|Study Completion Date :||April 2014|
No Intervention: Centers for Disease Control and Prevention (CDC) Fact Sheet
Participants will receive the CDC Fact sheet about HPV vaccination while they are taking the survey.
Experimental: MeFirst Intervention
Participants will receive a tailored website regarding their own individualized risk for HPV and information about HPV Vaccination while they are taking the survey as opposed to receiving the CDC fact sheet. This tailored website is generated based on answers provided by each subject in the baseline survey.
Behavioral: MeFirst Tailored Intervention
Participants will be lead through MeFirst, an interactive web-based tool that is tailored to their responses during the survey. This tool provides information regarding HPV Vaccination.
- Determine the effect of the MeFirst tool, a tailored, online HPV vaccination decision-making guide, on HPV vaccination intention and/or uptake. [ Time Frame: Immediately post intervention, 3 months and 12 months ]Intention will be assessed on a five-point scale immediately after and at 3 and 12 months. Uptake will be assessed by yes/no/don't know response to the statement, "I have received at least 1 dose of the HPV vaccine" at 3 and 12 months.
- Determine the effect of the MeFirst tool on HPV-related knowledge. [ Time Frame: Immediately post intervention, 3 months and 12 months ]Comparing 5 or 10-point scales measuring participants' HPV-related knowledge (HPV, HPV vaccination, and cervical cancer) immediately post-intervention and at 3 months and 12 months.
- Determine acceptability of the MeFirst tool to participants. [ Time Frame: Immediately post intervention, 3 months and 12 months ]Participants answer five 5-point scale questions about the acceptability of the MeFirst tool immediately post intervention, and at 3 months and 12 months.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01769560
|United States, Michigan|
|Univeristy of Michigan|
|Ann Arbor, Michigan, United States, 48109|
|Principal Investigator:||Vanessa K Dalton, MD, MPH||University of Michigan|